FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134649517> ?p ?o ?g. }

• W2134649517 endingPage "972" @default.
• W2134649517 startingPage "965" @default.
• W2134649517 abstract "High-dose chemotherapy followed by blood or marrow transplantation (BMT) is generally considered the best salvage option for patients with relapsed diffuse large-B-cell non-Hodgkin's lymphoma (DLCL). The relative roles for allogeneic and autologous BMT remain controversial. We reviewed the clinical outcome of 183 patients with relapsed DLCL who underwent BMT at Johns Hopkins University in 1985-2001. A total of 45 patients received T-cell-depleted HLA-matched allogeneic bone marrow (allo-BMT), and 138 patients received autologous marrow or peripheral blood stem cells (auto-BMT). The allo-BMT recipients had a higher proportion of patients with chemoresistant disease (P = .004) and had received more chemotherapy before BMT (P = .02). The auto-BMT recipients were older (P < .001) and were of more advanced-stage disease (P = .01). The 3-year overall survival (OS) was 23.7% (median survival, 129 days) after allo-BMT and 33.1% (median survival, 263 days), after auto-BMT (log-rank, P = .17). The 3-year OS for patients with sensitive disease was 51.9% after allo-BMT and 46.2% after auto-BMT (log-rank, P = .38). For patients with resistant disease, the 3-year OS was 12.1% after allo-BMT and 19.1% after auto-BMT (log rank, P = .08). In multivariate analysis, significant predictors of death were disease sensitivity (hazard rate [HR], 0.3; 95% confidence interval [CI] 0.2-04; P < .001), age >40 years (HR, 2.42; 95% CI, 1.7-3.4; P < .001), and stage at diagnosis (HR, 1.2; 95% CI, 1.0-1.4; P = .04). The 3-year event-free survival (EFS) for patients with sensitive disease was 52.7% after allo-BMT and 42.0% after auto-BMT (log-rank, P = .29). For patients with resistant disease, the 3-year EFS was 6.2% after allo-BMT and 19.4% after auto-BMT (log-rank, P = .1). The 3-year probability of relapse for chemosensitive patients was 30% after allo-BMT and 46.1% after auto-BMT (log-rank, P = .25). The 3-year relapse rate in patients with resistant disease was 75.0% after allo-BMT and 69.9% after auto-BMT (log-rank, P = .58). In multivariate analysis, only disease sensitivity status (HR, 0.4; 95% CI, 0.2-2.1; P < .001) and age >40 years (HR, 1.7; 95% CI, 1.1-2.9; P = .03) appear to have a significant impact on relapse. Transplant-related mortality (TRM) was the cause of death for 51.1% of allo-BMT recipients and 23.9% of auto-BMT recipients (P < .001). Mortality from lymphoma was 26.6% in allo-BMT recipients and 43.5% in auto-BMT recipients (P = .02). Auto-BMT and allo-BMT produced similar survival for patients with relapsed DLCL. For patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was achieved at the cost of greater TRM." @default.
• W2134649517 created "2016-06-24" @default.
• W2134649517 creator A5008197704 @default.
• W2134649517 creator A5011559739 @default.
• W2134649517 creator A5019890854 @default.
• W2134649517 creator A5036664711 @default.
• W2134649517 creator A5068593672 @default.
• W2134649517 date "2006-09-01" @default.
• W2134649517 modified "2023-10-04" @default.
• W2134649517 title "Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma" @default.
• W2134649517 cites W1842391090 @default.
• W2134649517 cites W1914133119 @default.
• W2134649517 cites W1955081269 @default.
• W2134649517 cites W1964751875 @default.
• W2134649517 cites W1968077178 @default.
• W2134649517 cites W1997353354 @default.
• W2134649517 cites W2005467291 @default.
• W2134649517 cites W2076261964 @default.
• W2134649517 cites W2083117934 @default.
• W2134649517 cites W2154402133 @default.
• W2134649517 cites W2261523254 @default.
• W2134649517 cites W2273212049 @default.
• W2134649517 cites W2273350722 @default.
• W2134649517 cites W2313423582 @default.
• W2134649517 cites W2314181999 @default.
• W2134649517 cites W2320777952 @default.
• W2134649517 cites W2327744514 @default.
• W2134649517 cites W2338377114 @default.
• W2134649517 cites W2339381415 @default.
• W2134649517 cites W2339392195 @default.
• W2134649517 cites W4232937072 @default.
• W2134649517 cites W4252168887 @default.
• W2134649517 cites W4293241248 @default.
• W2134649517 cites W64930248 @default.
• W2134649517 doi "https://doi.org/10.1016/j.bbmt.2006.05.018" @default.
• W2134649517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16920563" @default.
• W2134649517 hasPublicationYear "2006" @default.
• W2134649517 type Work @default.
• W2134649517 sameAs 2134649517 @default.
• W2134649517 citedByCount "41" @default.
• W2134649517 countsByYear W21346495172012 @default.
• W2134649517 countsByYear W21346495172013 @default.
• W2134649517 countsByYear W21346495172014 @default.
• W2134649517 countsByYear W21346495172015 @default.
• W2134649517 countsByYear W21346495172016 @default.
• W2134649517 countsByYear W21346495172017 @default.
• W2134649517 countsByYear W21346495172018 @default.
• W2134649517 countsByYear W21346495172019 @default.
• W2134649517 countsByYear W21346495172020 @default.
• W2134649517 countsByYear W21346495172021 @default.
• W2134649517 crossrefType "journal-article" @default.
• W2134649517 hasAuthorship W2134649517A5008197704 @default.
• W2134649517 hasAuthorship W2134649517A5011559739 @default.
• W2134649517 hasAuthorship W2134649517A5019890854 @default.
• W2134649517 hasAuthorship W2134649517A5036664711 @default.
• W2134649517 hasAuthorship W2134649517A5068593672 @default.
• W2134649517 hasBestOaLocation W21346495171 @default.
• W2134649517 hasConcept C126322002 @default.
• W2134649517 hasConcept C141071460 @default.
• W2134649517 hasConcept C143998085 @default.
• W2134649517 hasConcept C146357865 @default.
• W2134649517 hasConcept C151730666 @default.
• W2134649517 hasConcept C207103383 @default.
• W2134649517 hasConcept C2776694085 @default.
• W2134649517 hasConcept C2779338263 @default.
• W2134649517 hasConcept C2780007613 @default.
• W2134649517 hasConcept C2911091166 @default.
• W2134649517 hasConcept C44249647 @default.
• W2134649517 hasConcept C71924100 @default.
• W2134649517 hasConcept C86803240 @default.
• W2134649517 hasConcept C90924648 @default.
• W2134649517 hasConceptScore W2134649517C126322002 @default.
• W2134649517 hasConceptScore W2134649517C141071460 @default.
• W2134649517 hasConceptScore W2134649517C143998085 @default.
• W2134649517 hasConceptScore W2134649517C146357865 @default.
• W2134649517 hasConceptScore W2134649517C151730666 @default.
• W2134649517 hasConceptScore W2134649517C207103383 @default.
• W2134649517 hasConceptScore W2134649517C2776694085 @default.
• W2134649517 hasConceptScore W2134649517C2779338263 @default.
• W2134649517 hasConceptScore W2134649517C2780007613 @default.
• W2134649517 hasConceptScore W2134649517C2911091166 @default.
• W2134649517 hasConceptScore W2134649517C44249647 @default.
• W2134649517 hasConceptScore W2134649517C71924100 @default.
• W2134649517 hasConceptScore W2134649517C86803240 @default.
• W2134649517 hasConceptScore W2134649517C90924648 @default.
• W2134649517 hasIssue "9" @default.
• W2134649517 hasLocation W21346495171 @default.
• W2134649517 hasLocation W21346495172 @default.
• W2134649517 hasOpenAccess W2134649517 @default.
• W2134649517 hasPrimaryLocation W21346495171 @default.
• W2134649517 hasRelatedWork W1900595920 @default.
• W2134649517 hasRelatedWork W1987468340 @default.
• W2134649517 hasRelatedWork W2003938723 @default.
• W2134649517 hasRelatedWork W2047967234 @default.
• W2134649517 hasRelatedWork W2114624491 @default.
• W2134649517 hasRelatedWork W2141506168 @default.
• W2134649517 hasRelatedWork W2194631636 @default.
• W2134649517 hasRelatedWork W2439875401 @default.

• next